Search criteria | ||||
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | ||||
Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group | ||||
"1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" | ||||
"Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October" |
||||
, Article | ||||
, Denmark, Finland, Germany, Norway, Spain, Sweden, UK | ||||
Abstract: https://doi.org/10.1016/j.diabet.2022.101418 (https://www.sciencedirect.com/science/article/pii/S1262363622000994) | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care | |
Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study | ||||
Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group | ||||
"1 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 2 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 3 Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea 4 Kansai Electric Power Medical Research Institute, Kobe, Japan 5 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 6 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 7 Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan 8 Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan 9 National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan 10 Department of Cardiovascular Medicine, Saga University, Saga, Japan 11 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan 12 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan 13 Boehringer Ingelheim Korea Ltd, Seoul, Korea 14 IQVIA, Espoo, Finland 15 Boehringer Ingelheim International GmbH, Ingelheim, Germany 16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA 17 Kansai Electric Power Hospital, Osaka, Japan " | ||||
"JDI journal Virtual Conference: ACC, May 2021" |
||||
, Article | ||||
, Japan, Korea, Taiwan | ||||
Abstract: https://doi.org/10.1111/jdi.13959 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study | 2023 | English | , Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis | |
Georgraphic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States | ||||
Danni Zhao, Jonggyu Baek, Anne L Hume, Emily A McPhillips, and Kate L Lapane | ||||
1Department of Population and Quantitative Health Sciences, UMass Chan Medical School, Worcester, MA, USA. 2Department of Family Medicine, Alpert Medical School, Brown University, Memorial Hospital of Rhode Island, Providence, RI, USA. 3Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA. | ||||
J Pain Res . 2022 Feb 11;15:443-454. doi: 10.2147/JPR.S345521. eCollection 2022. |
||||
, Article | ||||
, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/35177933/ | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Pain | 2022 | English | , Epidemiological study, Observational study, Public Health | |
The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a | ||||
Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group | ||||
IQVIA Netherlands, Real World Evidence, Netherlands b Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands c Medical University of Graz, Graz, Austria d Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany e St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands | ||||
eNeurologicalSci, Volume 28, 2022, 100409, ISSN 2405-6502, https://doi.org/10.1016/j.ensci.2022.100409. (https://www.sciencedirect.com/science/article/pii/S2405650222000181) |
||||
, Article | ||||
, Austria, Belgium, Netherlands , Slovakia | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S2405650222000181 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Drug Utlization Study, Neurological disorders | 2022 | English | , Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study | |
Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018 | ||||
Janet Sultana 1 2, Salvatore Crisafulli 3, Mariana Almas 4, Ippazio Cosimo Antonazzo 5 6, Esme Baan 7, Claudia Bartolini 6, Maria Paola Bertuccio 3, Fedele Bonifazi 8 9, Annalisa Capuano 10 11, Antonella Didio 8 9, Vera Ehrenstein 12, Mariagrazia Felisi 8 13, Carmen Ferrajolo 10 11, Andrea Fontana 14, Remy Francisca 7, Annie Fourrier-Reglat 15, Joan Fortuny 16, Rosa Gini 6, Giulia Hyeraci 6, Christel Hoeve 7, Christos Kontogiorgis 17, Valentina Isgrò 18, Panagiotis-Nikolaos Lalagkas 17, Luca L'Abbate 18, Deborah Layton 19, Annalisa Landi 8 9, Silvia Narduzzi 19, Leonardo Roque Pereira 20, Georgios Poulentzas 17, Concetta Rafaniello 10 11, Giuseppe Roberto 6, Giulia Scondotto 3, Liberata Sportiello 10 11, Maddalena Toma 8 9, Massoud Toussi 19, Katia Verhamme 7, Elisabetta Volpe 8 9, Gianluca Trifirò 18, | ||||
Pharmacy Department, Mater Dei Hospital, Msida, Malta. 2Exeter College of Medicine and Health, Exeter, UK. 3Department of Medicine, University of Verona, Verona, Italy. 4Real World Solutions Department, IQVIA, Lisbon, Portugal. 5Research Centre on Public Health (CESP), University of Milan-Bicocca, Milan, Italy. 6Agenzia Regionale di Sanità della Toscana, Florence, Italy. 7Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands. 8TEDDY European Network of Excellence for Paediatric Clinical Research, Pavia, Italy. 9Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Bari, Italy. 10Department of Experimental Medicine, University of Campania "Vanvitelli", Naples, Italy. 11Campania Regional Center of Pharmacovigilance and Pharmacoepidemiology, Naples, Italy. 12Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 13CVBF Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy. 14Unit of Biostatistics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. 15Univ. Bordeaux, INSERM, Bordeaux Population Health Research Center, Team of Pharmacoepidemiology, UMR 1219, Bordeaux, France. 16RTI Health Solutions, Barcelona, Spain. 17Democritus University of Thrace, Alexandroupolis, Greece. 18Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 19Data Science Hub, Real World Solutions, IQVIA, London, UK. 20Department of Datascience & Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands. | ||||
Pharmacoepidemiol Drug Saf . 2022 Jun;31(6):689-705. doi: 10.1002/pds.5413. Epub 2022 Feb 11. |
||||
, Article | ||||
, Denmark, France, Italy, Netherlands, Portugal, Spain, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/35092329/ | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Drug Utlization Study | 2022 | English | , Database Study, Review | |
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study | ||||
Farah Toron 1, Maureen P Neary 2, Timothy W Smith 3, David Gruben 4, William Romero 5, Amy Cha 3, Keyur Patel 1, Simona Z Vasileva 6, Mahreen Ameen 7 | ||||
1Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA. 3Inflammation & Immunology, Pfizer Inc, New York, New York, USA. 4Global Biometrics and Data Management (Statistics), Pfizer Inc, Groton, Connecticut, USA. 5Inflammation & Immunology, Pfizer Ltd, Surrey, UK. 6Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. simona.vasileva@iqvia.com. 7Royal Free London National Health Services Foundation Trust, London, UK. | ||||
PMID: 33846907 PMCID: PMC8163940 DOI: 10.1007/s13555-021-00519-7 |
||||
, Article | ||||
, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33846907/ | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Drug Utlization Study, Methodology | 2021 | English | , direct to patient research, direct-to-patient research, Economic evaluation, Population Based Study, Retrospective database analysis | |
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden | ||||
Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5 | ||||
1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA | ||||
ECTRIMS 2021, Digital, 13-15 October 2021 |
||||
, Abstract | ||||
, Finland, Sweden | ||||
Abstract: https://ectrims2021.abstractserver.com/program/#/details/presentations/466 | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2021 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis | |
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden | ||||
Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5 | ||||
1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA | ||||
ECTRIMS 2021, Digital, 13-15 October 2021 |
||||
, Poster | ||||
, Finland, Sweden | ||||
Abstract: http://medpub-poster.merckgroup.com/ECTRIMS2021_INFORM_Study_Design.pdf | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2021 | English | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis | |
Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014 | ||||
Pocobelli G, Dublin S, Bobb JF, Albertson-Junkans L, Andrade S, Cheetham TC, Salgado G, Griffin MR, Raebel MA, Smith D, Li DK, Pawloski PA, Toh S, Taylor LG, Hua W, Horn P, Trinidad JP, Boudreau DM | ||||
"L Taylor: EPI OR, RWS, IQVIA; 1Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA. 2Meyers Primary Care Institute, Worcester, Massachusetts, USA. 3Kaiser Permanente Southern California, Department of Research & Evaluation, Pasadena, CA, Chapman University, School of Pharmacy, Irvine, CA, USA. 4Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 5Institute for Health Research, Kaiser Permanente Colorado, Colorado, USA. 6Kaiser Permanente Center for Health Research, Portland, Oregon, USA. 7Kaiser Foundation Research Institute, Oakland, California, USA. 8Health Partners Institute, Bloomington, Minnesota, USA. 9Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. 10Food and Drug Administration, Silver Spring, Maryland, USA." | ||||
Pharmacoepidemiol Drug Saf. 2021 Nov;30(11):1541-1550. doi: 10.1002/pds.5312. |
||||
, Article | ||||
, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/34169607/ | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Womens Health | 2021 | English | , Epidemiological study, Population Based Study | |
Monitoring outpatient antibiotic utilization using reimbursement and retail sales data: a population-based comparison in France, 2012-17 | ||||
Nhung T H Trinh 1 2, Martin Chalumeau 1 3, Tim A Bruckner 4, Corinne Levy 5 6, Antoine Bessou 2, Dejan Milic 2, Robert Cohen 5 7, Magali Lemaitre 2, Jérémie F Cohen 1 3 | ||||
1Université de Paris, Epidemiology and Statistics Research Center-CRESS, INSERM, Obstetrical, Perinatal and Pediatric Epidemiology research team, F-75004, Paris, France. 2IQVIA, La Défense, France. 3Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Hôpital Necker-Enfants malades, Université de Paris, Paris, France. 4Program in Public Health, University of California, Irvine, CA, USA. 5Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Saint-Maur-des-Fossés, France. 6Clinical Research Centre, Centre Hospitalier Intercommunal de Créteil, Créteil, France. 7Université Paris Est, IMRB-GRC GEMINI, Créteil, France. | ||||
J Antimicrob Chemother . 2021 Aug 12;76(9):2446-2452. doi: 10.1093/jac/dkab185. |
||||
, Article | ||||
, France | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/34120188/ | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2021 | English | , Population Based Study | |
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study | ||||
Gerard E.Franciscoa; Daniel S.Bandari; Ganesh Bavikattec; Wolfgang H.Jost; Emily McCusker; Joan Largent; Alekse Zuzek; Alberto Esquenazi | ||||
a The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA b Multiple Sclerosis Center of California & Research Group, Newport Beach, CA, USA c The Walton Centre, Liverpool, UK d University of Freiburg, Department of Neurology, Freiburg im Breisgau, Germany e Parkinson-Klinik Ortenau, Wolfach, Germany f Allergan, an AbbVie Company, Irvine, CA, USA g IQVIA Real-World Evidence Solutions, Cambridge, MA, USA h MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA | ||||
PM R . 2020 Jan 17. doi: 10.1002/pmrj.12328. PMID: 31953896 DOI: 10.1002/pmrj.12328 |
||||
, Article | ||||
, Asia Pacific, Europe, USA | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S2590171020300187?via%3Dihub | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Medication compliance | 2020 | English | , Methodology, Observational study | |
A systematic literature review of the disease and economic burden of multidrug resistance gram negative infections (MRGN) in Japan | ||||
T Hara 1, H Ikeoka 1, Adeeb Tawseef 2, Ryo Mitsuo 2 (rwesheorj 2) | ||||
1) Shionogi & Co., Ltd., Osaka, Japan 2) IQVIA Solutions Japan KK, Tokyo, Japan | ||||
ISPOR Asia Pacific 2020 Conference |
||||
, Abstract | ||||
, Japan | ||||
Abstract: https://www.ispor.org/heor-resources/presentations-database/presentation/asia2020-3264/103814 | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2020 | English | , Burden of illness, Literature Review | |
Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions | ||||
Kristin M Sheffield , Nancy A Dreyer , James F Murray, Douglas E Faries & Megan N Klopchin | ||||
1Global Patient Outcomes & Real World Evidence, Eli Lilly & Company, Indianapolis, IN 46225, USA 2IQVIA Real-World & Analytic Solutions, Cambridge, MA 02139, USA 3Real World Analytics, Eli Lilly & Company, Indianapolis, IN 46225, USA | ||||
Published Online:11 Sep 2020https://doi.org/10.2217/cer-2020-0161 |
||||
, Article | ||||
, USA | ||||
Abstract: https://www.futuremedicine.com/doi/10.2217/cer-2020-0161 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Drug Utlization Study, Guidelines, Methodology, Public Health | 2020 | English | , Methodology, Observational study, Population Based Study | |
Patrones de tratamiento biológico en pacientes con enfermedades articulares inflamatorias. Estudio retrospectivo de 4 años de seguimiento | ||||
Juan D. Cañete1, Antonio Naranjo2, Javier Calvo3, Carmen Ordás4, Belén Aragón5, Gonzalo Nocea5, Montse Roset6, Antonio Fernández-Nebro7 | ||||
1 Servicio de Reumatología, Hospital Clínic e IDIBAPS, Barcelona, España 2 Departamento de Reumatología, Hospital Dr. Negrín, Universidad de las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España 3 Departamento de Reumatología, Hospital General Universitario de Valencia, Valencia, España 4 Departamento de Reumatología, Hospital de Cabueñes, Gijón, España 5 Departamento de Health Economics and Outcomes Research, MSD, Madrid, España 6 Departamento de Health Economics and Outcomes Research, IQVIA, Barcelona, España 7 Departamento de Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, España | ||||
Reumatología Clínica, 2019. DOI: 10.1016 |
||||
, Article | ||||
, Spain | ||||
Abstract: http://reumatologiaclinica.org/es-patrones-tratamiento-biologico-pacientes-con-avance-S1699258X18302596 | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2019 | Spanish | , Clinical setting: hospital, Observational study | |
Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe | ||||
Fife D, Waller J, Kaplan S, Hu P, Phillips S, Oliveria SA, Richarz U | ||||
Fife: Janssen Research and Development, LLC Waller: Adephi Real World Kaplan: Teva Pharmaceutical Indusries Ltd. Hu: Janssen Global Services Phillips: IQVIA Oliveria, IQVIA Richarz: Janssen Research and Development, LLC | ||||
Clin Drug Investig (2019). https://doi.org/10.1007/s40261-019-00831-3 |
||||
, Article | ||||
, Belgium, France, Germany, Spain, UK | ||||
Abstract: https://link.springer.com/article/10.1007/s40261-019-00831-3 | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Drug Utlization Study | 2019 | English | , Population Based Study, Retrospective database analysis | |
A population-based analysis of anti-diabetic medications in four Canadian provinces: secular trends and prescribing patterns | ||||
Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, and Filion KB | ||||
IQVIA, Cambridge, MA | ||||
Pharmacoepidemiology & Drug Safety (in press) |
||||
, Article, In press/to be published | ||||
, Canada | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Drug Utlization Study | 2019 | English | , Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis | |
Determining Real-World Data’s Fitness for Use and the Role of Reliability | ||||
Nirosha Mahendraratnam Christina Silcox Kerra Mercon Adam Kroetsch Morgan Romine Nicholas Harrison Adam Aten Rachel Sherman Gregory Daniel* Mark McClellan | ||||
The Robert J. Margolis, MD, Center for Health Policy at Duke University is directed by Mark McClellan, MD, PhD, and brings together expertise from the Washington, DC, policy community, Duke University, and Duke Health to address the most pressing issues in health policy. The mission of Duke-Margolis is to improve health and the value of health care through practical, innovative, and evidence-based policy solutions. Duke-Margolis catalyzes Duke University’s leading capabilities, including interdisciplinary academic research and capacity for education and engagement, to inform policy making and implementation for better health and health care. For more information, visit healthpolicy.duke.edu. | ||||
https://healthpolicy.duke.edu/sites/default/files/atoms/files/_determining_real-world_datas_fitness_for_use_and_the_role_of_reliability.pdf |
||||
, Health authorities guidelines/assessment report, Report | ||||
Abstract: https://healthpolicy.duke.edu/publications/determining-real-world-data’s-fitness-use-and-role-reliability | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Health policy | 2019 | English | , Retrospective database analysis | |
PRS72 DRUG TREATMENT PATTERNS FOR PULMONARY ARTERIAL HYPERTENSION PATIENTS IN ENGLAND: A RETROSPECTIVE ANALYSIS USING HOSPITAL TREATMENT INSIGHTS DATABASE | ||||
A. Beaudet A. Yesufu-Udechuku E.W. Davies L.H. Taylor S. Sikander-Rehman R. Ogley F. Exposto | ||||
Actelion Pharmaceuticals Ltd., Allschwill, BL, Switzerland Actelion Pharmaceuticals UK Ltd, London, UK Actelion Pharmaceuticals Ltd., Allschwill, BL, Switzerland IQVIA, London, UK | ||||
Open ArchiveDOI:https://doi.org/10.1016/j.jval.2019.09.2561 |
||||
, Poster | ||||
, England | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)34939-3/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug safety, Drug Utlization Study, Health status & patient reported outcomes | 2019 | English | , Public Health, Real World Data, Retrospective cohort analysis, Retrospective Field Study | |
Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK | ||||
Anthony Bewley 1, Cristiana Miglio 2, Haijun Tian 3, Isabelle Gilloteau 4, Joannah Whitehead 5, Ruben Hermans 2 | ||||
1a Whipps Cross University Hospital , London , UK. 2b IQVIA , London , UK. 3c Novartis Pharmaceuticals Corporation , East Hanover , NJ , USA. 4d Novartis Pharma AG , Novartis Campus , Basel , Switzerland. 5e Novartis UK Pharmaceuticals Ltd , Frimley, Camberley , UK. | ||||
PMID: 30256686 DOI: 10.1080/09546634.2018.1524820 |
||||
, Article | ||||
, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/30256686/ | ||||
Condition | Year | Language | Analysis type | |
, Drug safety, Drug Utlization Study, Guidelines, Health status & patient reported outcomes | 2019 | English | , direct-to-patient research, Methodology, Survey research | |
5-ASA Prescription Trends over Time in Inflammatory Bowel Disease 1996 to 2015-A UK Population-Based Study | ||||
Jaraith, V, S Hokkanen, L Guizzetti, N Boxall, S Campbell-Hill, and H Patel | ||||
Western University, Department of Medicine, London, Ontario, Canada, Robarts Clinical Trials Inc., London, Ontario, Canada, IQVIA, London, UK, | ||||
Journal of Crohn, no. Supplement 1 (February): S309–10 |
||||
, Abstract | ||||
, UK | ||||
Abstract: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018/item/p405-5-asa-prescription-trends-over-time-in-inflammatory-bowel-disease-1996-to-2015-x2013-a-uk-population-based-study.html | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Drug Utlization Study, Gastrointestinal disorders | 2018 | English | , Epidemiological study, Retrospective cohort analysis | |
The Impact of Risk Minimization Measures on Compliance and Prescribing Practices of Flupirtine in Germany. | ||||
Kaplan S, Ehlken B, Hamann X | ||||
Teva Pharmaceutical Industries Ltd , Petach Tikva , Israel. IQVIA (formerly IMS Health) , Munich , Germany. Ratiopharm GmbH (an affiliate of Teva Pharmaceuticals Europe BV) , Ulm , Germany | ||||
Curr Med Res Opin |
||||
, Article | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Medication compliance | 2018 | English | , Retrospective cohort analysis | |
Treatment Patterns, Adherence, and Persistence among Psoriasis Patients Treated with Biologics in a Real-World Setting, Overall and by Disease Severity | ||||
Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Zbrozek A, Araujo AB | ||||
Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: cBrigham and Women’s | ||||
Journal of Dermatological Treatment |
||||
, Article | ||||
, USA | ||||
Abstract: https://www.tandfonline.com/doi/abs/10.1080/09546634.2018.1479725?journalCode=ijdt20 | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Drug Utlization Study, Patient Registries & Real-World Study Methods | 2018 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis | |
Real-World Use of Dulaglutide in Europe: A Multi-Country Drug Utilization Study | ||||
Ali AK, Toussi M, Phillips S, Roste M | ||||
Ali AK: Eli Lilly and Company; Toussi M: IQVIA; Phillips S: IQVIA; Roste M: IQVIA | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, France, Germany, Spain, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Drug Utlization Study, Drug Utlization Study | 2018 | English | , Database Study, Epidemiological study | |
Adherence and Persistence to Biologics Among Psoriasis Patients, Overall and by Disease Severity | ||||
Murage MJ, Anderson A, Oliveria SA, Al Sawah S, Casso D, Malatestinic WN, Tanaka Y, Muram TM, Ojeh CK, Zbrozek A, Araujo AB | ||||
Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Al Sawah S: Eli Lilly and Company; Casso D: IQVIA; Malatestinic WN: Eli Lilly and Company; Tanaka Y: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Ojeh CK: Eli Lilly and Company; Zbrozek A: Eli Lilly and Company, Araujo AB: Eli Lilly and Company | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Dermatology, Drug Utlization Study, Urology | 2018 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis | |
Healthcare Resource Utilization and Costs Among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity | ||||
Al Sawah S, Anderson A, Casso D, Murage MJ, Oliveria SA, Malatestinic WN, Tanaka Y, Muram TM, Ojeh CK, Zbrozek A, Araujo AB | ||||
Al Sawah S: Eli Lilly and Company; Anderson A: IQVIA; Casso D: IQVIA; Murage MJ: Eli Lilly and Company; Oliveria SA: IQVIA; Malatestinic WN: Eli Lilly and Company; Tanaka Y: Eli Lilly and Company; Muram TM, Ojeh CK: Eli Lilly and Company; Zbrozek A, Araujo AB: Eli Lilly and Company | ||||
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Drug Utlization Study, Patient Registries & Real-World Study Methods | 2018 | English | , Database Study, Epidemiological study, Retrospective database analysis | |
Chapter 4.1 Drug Utilisation and Prescription-Event Monitoring | ||||
Massoud Toussi and Deborah Layton | ||||
IQVIA, Cedex France; IQVIA, London | ||||
, Book chapter | ||||
, England | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2018 | English | , Epidemiological study | |
A Data-driven Methodology to Define and visualise Line of Therapy for Real-World Data Epidemiology of Cancers. | ||||
ALI ABBASI1, Ruben Hermans1, Dony Patel1, Fiona Grimson1, Peter McMahon1, Joseph Kim1, Eric S Groves2 and Deborah Layton1. | ||||
1IQVIA, LONDON, United Kingdom, 2IQVIA, San Diego, CA | ||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2018 | English | , Epidemiological study | |
A Data-driven Methodology to Define and visualise Line of Therapy for Real-World Data Epidemiology of Cancers. | ||||
ALI ABBASI1, Ruben Hermans1, Dony Patel1, Fiona Grimson1, Peter McMahon1, Joseph Kim1, Eric S Groves2 and Deborah Layton1. | ||||
1IQVIA, LONDON, United Kingdom, 2IQVIA, San Diego, CA | ||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2018 | English | , Epidemiological study | |
Télémédecine et dépenses de santé – une modélisation économique évaluant l’impact d’une intervention en télémédecine dans trois pathologies chroniques : diabète de type 2, hypertension artérielle et cancer de la prostate. | ||||
S. Sclison, C. Le Pen, I. Bardoulat, A. Gayon, C. Kolahi, M. Belhassen, F. Depont, E. Van Ganse | ||||
a IQVIA, Courbevoie, France b Pharmaco-épidémiologie Lyon (PELyon), Lyon, France | ||||
Doi : 10.1016/j.respe.2018.04.053 |
||||
, Article | ||||
, France | ||||
Abstract: https://www.em-consulte.com/article/1215540/telemedecine-et-depenses-de-sante-%E2%80%93%C2%A0une-modelisati | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2018 | French | , Observational study, Population Based Study | |
The impact of physician-level drug budgets on prescribing behaviour | ||||
Fischer KE; Koch T; Kostev K; Stargardt T | ||||
Eur J Health Econ. 2017 Feb 13. doi: 10.1007/s10198-017-0875-9. [Epub ahead of print] |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Health policy | 2017 | English | ||
Modelización del comportamiento de fármacos biosimilares en 5 países de europa [Modeling of the behavior of biosimilar drugs in 5 European countries]. | ||||
Manganelli AG1, Solozabal M2, Planellas L2, Rebollo P2, Puig-Junoy J1 | ||||
1 CRES - Universitat Pompeu Fabra, Barcelona, Spain 2 QuintilesIMS, RWI, Barcelona, Spain | ||||
XXXVII Jornadas de Economía de la Salud, 2017, 6 - 8 de septiembre, Barcelona, España |
||||
, Poster | ||||
, France, Germany, Italy, Spain, UK | ||||
Abstract: http://www.aes.es/jornadas/es/#comunicaciones | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Drug Utlization Study | 2017 | Spanish | , Clinical setting: hospital | |
Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom | ||||
Feher M, Vega-Hernandez G, Mocevic E, Buysse B, Myland M, Power GS, Nystrup Husemoen LL, Kim J & Witte DR | ||||
Chelsea and Westminster Hospital | ||||
Diabetes Therapy |
||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Drug Utlization Study | 2017 | English | , Retrospective database analysis | |
Healthcare Resource Utilization and Costs Among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity | ||||
Al Sawah S, Anderson A, Casso D, Murage MJ, Oliveria SA, Malatestinic WN, Tanaka Y, Muram TM, Ojeh CK, Zbrozek A, Araujo AB | ||||
Al Sawah S: Eli Lilly and Company; Anderson A: IQVIA; Casso D: IQVIA; Murage MJ: Eli Lilly and Company; Oliveria SA: IQVIA; Malatestinic WN: Eli Lilly and Company; Tanaka Y: Eli Lilly and Company; Muram TM, Ojeh CK: Eli Lilly and Company; Zbrozek A, Araujo AB: Eli Lilly and Company | ||||
The Academy of Managed Care Pharmacy® NEXUS; Dallas, TX |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Drug Utlization Study, Patient Registries & Real-World Study Methods | 2017 | English | , Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis | |
Adherence and Persistence to Biologics Among Psoriasis Patients, Overall and by Disease Severity | ||||
Murage MJ, Anderson A, Oliveria SA, Al Sawah S, Casso D, Malatestinic WN, Tanaka Y, Muram TM, Ojeh CK, Zbrozek A, Araujo AB | ||||
Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Al Sawah S: Eli Lilly and Company; Casso D: IQVIA; Malatestinic WN: Eli Lilly and Company; Tanaka Y: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Ojeh CK: Eli Lilly and Company; Zbrozek A: Eli Lilly and Company, Araujo AB: Eli Lilly and Company | ||||
The Academy of Managed Care Pharmacy® NEXUS; Dallas, TX |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Dermatology, Drug Utlization Study | 2017 | English | , Database Study, Epidemiological study, Retrospective database analysis | |
Effectiveness of a Risk-Minimization Activity Involving Physician Education on Metabolic Monitoring of Patients Receiving Quetiapine: Results from Two Post-Authorization Safety Studies | ||||
Robert S. Brody, Charles L. Liss, Heather Wray, Ramon Iovin, Carmen Michaylira, Anushini Muthutantri, Philip Damstetter, Catherine Datto, Leigh Jefferies | ||||
Int Clin Psychopharmacol. 2016 Jan;31(1):34-41. |
||||
, Article | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2016 | English | , Survey research | |
Drug Utilization Study for Lisdexamfetamine Dimesylate (LDX) in Australia | ||||
von Bredow D1, Ehlken B1, Blumentals WA2, Kolb N1, Keja J1, Maxwell T2 | ||||
1 IMS HealthGmbH & Co. OHG, Munich, Germany, 1 Shire Pharmaceuticals, Lexington, MA, USA | ||||
32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) |
||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2016 | English | , Database Study, Survey research | |
Excess Healthcare Resource Utilization in Obesity Pharmacotherapy Candidates in Canada | ||||
Feroz T1, Charland K2, Heembrock S2, Borrelli R2, Skovgaard R1 | ||||
1 NovoNordisk Canada Inc. Canada 2 IMS Brogan Canada | ||||
13th International Conference on Obesity, 2016, May 1-4, Vancouver, Canada |
||||
, Poster | ||||
, Canada | ||||
Abstract: http://www.imsbrogancapabilities.com/pdf/rwe/obesity-conference-poster-2016.pdf | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Obesity | 2016 | English | , Retrospective cohort analysis | |
Pregabalin prescriptions in the United Kingdom: a drug utilisation study of The Health Improvement Network (THIN) primary care database | ||||
Asomaning K, Abramsky S, Liu Q, Zhou X, Sobel RE, Watt S | ||||
Department of Epidemiology, Pfizer Inc.; Department of Medical Affairs, Pfizer Inc | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Neurological disorders | 2016 | English | , Retrospective database analysis | |
Prevalence of antibiotic use: a comparison across various European health care data sources | ||||
Brauer R, Ruigómez A, Downey G, Bate A, Garcia Rodriguez LA, Huerta C, Gil M, de Abajo F, Requena G, Alvarez Y, Slattery J, de Groot M, Souverein P, Hesse U, Rottenkolber M, Schmiedl S, de Vries F, Tepie M, Schlienger R, Smeeth L, Douglas I, Reynolds R, Klungel O | ||||
(CEIFE); Amgen NV; Epidemiology, Pfizer Ltd; Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); Clinical Pharmacology Unit, University Hospital Príncipe de Asturias; Pharmacology Section, Department of Biomedical Sciences II, University of Alcalá (UAH); European Medicines Agency (EMA), London; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University; Lægemiddelstyrelsen (Danish Medicines Agency), National Institute for Health Data and Disease Control, Copenhagen; Institute of Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet Muenchen, Munich; Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University; Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal; MRC Lifecourse Epidemiology Unit, Southampton General Hospital, Southampton; School CAPHRI / Maastricht University, Maastricht; Novartis Pharma AG; Epidemiology, Pfizer Research & Development | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2016 | English | , Retrospective database analysis | |
Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data | ||||
O'Keeffe AG, Nazareth I, Petersen I | ||||
Department of Statistical Science, University College London; Department of Primary Care and Population Health, University College London | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug Utlization Study | 2016 | English | , Retrospective database analysis | |
Prasugrel Use in Real Life: A Report From the Outpatient Setting in France. | ||||
Sabouret P, Taiel-Sartral M, Chartier F, Akiki S, Cuisset T. | ||||
Clin Cardiol. 2016 Jul;39(7):378-84. doi: 10.1002/clc.22553. |
||||
, Article | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug Utlization Study | 2016 | English | ||
Characterizing treatment pathways at scale using the OHDSI network | ||||
George Hripcsaka,b,c,1, Patrick B. Ryanc,d, Jon D. Dukec,e, Nigam H. Shahc,f, Rae Woong Parkc,g, Vojtech Huserc,h, Marc A. Suchardc,i,j,k, Martijn J. Schuemiec,d, Frank J. DeFalcoc,d, Adler Perottea,c, Juan M. Bandac,f, Christian G. Reichc,l, Lisa M. Schillingc,m, Michael E. Mathenyc,n,o, Daniella Meekerc,p,q, Nicole Prattc,r, and David Madiganc,s | ||||
aDepartment of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032; bMedical Informatics Services, NewYork-Presbyterian Hospital, New York, NY 10032; cObservational Health Data Sciences and Informatics, New York, NY 10032; dEpidemiology Analytics, Janssen Research and Development, Titusville, NJ 08560; eCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN 46205; fCenter for Biomedical Informatics Research, Stanford University, CA 94305; gDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea, 443-380; hLister Hill National Center for Biomedical Communications (National Library of Medicine), National Institutes of Health, Bethesda, MD 20894; iDepartment of Biomathematics, University of California, Los Angeles, CA 90095; jDepartment of Biostatistics, University of California, Los Angeles, CA 90095; kDepartment of Human Genetics, University of California, Los Angeles, CA 90095; lReal World Evidence Solutions, IMS Health, Burlington, MA 01809; mDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO 80045; nDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37212; oGeriatric Research, Education and Clinical Center, VA Tennessee Valley Healthcare System, Nashville, TN 37212; pDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA 90089; qDepartment of Pediatrics, University of Southern California, Los Angeles, CA 90089; rDivision of Health Sciences, University of South Australia, Adelaide, SA, Australia 5001; and sDepartment of Statistics, Columbia University, New York, NY 10027 | ||||
Proceedings of the National Academy of Science of the United State of America - PNAS |
||||
, Article | ||||
, USA | ||||
Abstract: http://www.pnas.org/content/113/27/7329 | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Observational Health Data Sciences and Informatics (OHDSI) collaboration | 2016 | English | , Database Study, Retrospective database analysis | |
Impacto presupuestario del uso de un contraste isoosmolar frente a contrastes de baja osmolaridad en pacientes con alto riesgo de nefropatía inducida por contraste en el entorno hospitalario español | ||||
Eduardo Pinar1, José María Hernández2, Josepa Mauri3, Francisco Picó4, Rafael Ruiz5, Ángel Luis de Francisco6, Carmen Barrull7, Emilio Moreno8, Alexis Sampedro8, Felipe Hernández9 | ||||
1 Servicio de Hemodinámica, Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España; 2 Unidad de Hemodinámica, Hospital Virgen de la Victoria, Málaga, España; 3 Unitat d’Hemodinàmica i Cardiologia Intervencionista, Hospital Universitari Germans Trias i Pujol, Barcelona, España; 4 Unidad de Cardiología y Hemodinámica, Hospital Quirón, Murcia, España; 5 Servicio de Hemodinámica e Intervención Endovascular, Hospital Virgen Macarena, Sevilla, España; 6 Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, España; 7 Health Economics & Outcomes Research, IMS Health, Barcelona, España; 8 Departamento Médico, GE Healthcare, Madrid, España; 9 Servicio de Cardiología, Hospital Universitario Doce de Octubre, Madrid, España | ||||
PharmacoEcon Span Res Artic (2016) 13(1):17-24. |
||||
, Article | ||||
, Spain | ||||
Abstract: https://link.springer.com/article/10.1007%2Fs40277-015-0049-z | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug safety, Drug Utlization Study, Health economics | 2016 | Spanish | , Budget impact, Clinical setting: hospital | |
Utilisation and Dosage Patterns of Intravenous Echinocandins for Treatment of Invasive Fungal Infections Within Hospitals in England | ||||
Ahir HB1, McCann E2, Robertson S1, Patel S1, Yu E3, Tham R3 | ||||
1MSD Ltd, Hoddesdon, UK, 2Merck & Co., Kenilworth, NJ, USA, 3IMS Health, London, UK | ||||
Open ArchiveDOI:https://doi.org/10.1016/j.jval.2016.09.431 |
||||
, Poster | ||||
, UK | ||||
Abstract: https://www.valueinhealthjournal.com/action/showPdf?pii=S1098-3015%2816%2931798-3 | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study, Drug Utlization Study, Health status & patient reported outcomes | 2016 | English | , Clinical setting: Primary care, direct-to-patient research, Real World Evidence, Review | |
Prevention of venous thromboembolic events by fondaparinux 2.5mg in general practice. ArchiMed Ville | ||||
Mahé I1, Daurès JP2, Pouchain D3, Quéré I4, Aubin C5, Doussaint J6, Schück S6, Leroyer C7 | ||||
1EA 7334 méthodologies et société (REMES), hôpital Louis-Mourier, université Paris 7, AP-HP, 178, rue des Renouillers, 92700 Colombes, France. 2IURC de Montpellier, 641, avenue du Doyen-Gaston-Giraud, 34093 Montpellier cedex, France; CHU de Nîmes, 30029 Nîmes, France. 3Département de médecine générale, UFR Tours, 10, boulevard Tonnellé, BP 3223, 37032 Tours cedex 1, France. 4Hôpital Saint-Eloi, CHRU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. 5Laboratoire GlaxoSmithKline, 100, route de Versailles, 78160 Marly-le-roi, France. 6Kappa Santé, 4, rue de Cléry, 75002 Paris, France. 7Département de médecine interne et de pneumologie, université européenne de Bretagne, CHU de la Cavale-Blanche, boulevard Tanguy-Prigent, 29609 Brest cedex, France | ||||
J Mal Vasc. 2015 Jul 20. pii: S0398-0499(15)00121-3 |
||||
, Article | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug Utlization Study, Orthopedics, Regulatory, Vascular disease | 2015 | English | , Prospective study | |
Canadian Retrospective Claim Data Analysis of Biologics Switching and Retention Patterns in Psoriasis Patients (poster) | ||||
Millson B1, Poulin-Costello M2, Garces K2 | ||||
1 IMS Brogan, Kirkland, QC, Canada 2 Amgen Canada Inc., Mississauga, ON, Canada | ||||
ISPOR 20th Annual International Meeting |
||||
, Poster | ||||
, Canada | ||||
Abstract: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/54789 | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Drug Utlization Study | 2015 | English | , Retrospective database analysis | |
Trends of people using drugs and opioid substitute treatment recorded in England and wales general practice (1994-2012) | ||||
Davies HR, Nazareth I, Petersen I | ||||
University College London Department of Primary Care and Population Health | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Drug Utlization Study | 2015 | English | , Retrospective database analysis | |